The DNMT3A R882H mutant displays altered flanking sequence preferences.

Area of Science:

• Molecular Biology
• Cancer Genetics
• Biochemistry

Background:

• The DNMT3A R882H mutation is a common driver in acute myeloid leukemia (AML).
• This mutation is located at the DNA binding interface and is associated with reduced DNMT3A activity and dominant-negative effects.
• Understanding the precise molecular mechanisms is crucial for developing targeted therapies.

Purpose of the Study:

• To elucidate the mechanistic consequences of the DNMT3A R882H mutation.
• To investigate how the R882H mutation affects DNA methylation activity, binding, and sequence preference.
• To explore the implications of these changes for the role of DNMT3A in cancer.

Main Methods:

• Biochemical assays to assess DNA methylation activity, DNA binding affinity, protein stability, and subnuclear localization.
• DNA methylation experiments using various DNA substrates with specific flanking sequences.
• Kinetic analyses to quantify methylation rates for favored and disfavored substrates by wildtype and mutant DNMT3A.

Main Results:

• The DNMT3A R882H mutation caused an approximate 40% reduction in overall DNA methylation activity.
• R882H did not significantly alter DNA binding affinity, protein stability, or subnuclear distribution.
• Pronounced changes in flanking sequence preference were observed, with a 45% increased methylation rate for favored substrates and a 7-fold reduced rate for disfavored substrates compared to wildtype DNMT3A.

Conclusions:

• The R882H mutation alters DNMT3A's CpG site specificity by changing its preference for flanking DNA sequences.
• Residue 882 is involved in the indirect readout of DNA sequence preferences.
• These mutation-specific effects provide a mechanistic explanation for the enrichment of DNMT3A R882H in cancer patients.